Combination therapy delays progression for metastatic breast cancer patients

[News]

Phase III trial results show that a combination of the aromatase inhibitor anastrozole and fulvestrant, an analog of estradiol that downgrades the estrogen receptor, is superior to anastrozole alone in prolonging progression-free survival in patients with metastatic breast cancer.

More... (http://www.news-medical.net/news/20120810/Combination-therapy-delays-progression-for-metastatic-breast-cancer-patients.aspx)